MYNZ
MAINZ BIOMED N.V.
Key Financials
Operating Income
$-16139098
↑ 14.0%
Revenue
$537080
↓ 39.9%
Gross Profit
$389792
↓ 32.2%
Net Income
$-16210718
↑ 24.9%
Total Assets
$5.3M
↓ 60.5%
Total Liabilities
$4.7M
↓ 37.6%
EPS (Diluted)
$-2.70
↑ 87.7%
Shareholders' Equity
$641600.00
↓ 89.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/15/2026 | View on SEC |
| 10-K | 3/31/2026 | View on SEC |
| DEF 14A | 3/25/2026 | View on SEC |
| 8-K | 3/25/2026 | View on SEC |
| 8-K | 3/17/2026 | View on SEC |
| PRE 14A | 3/12/2026 | View on SEC |
| 8-K | 3/11/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 3 | 3/3/2026 | View on SEC |
| 4 | 2/19/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MYNZ |
| Company Name | MAINZ BIOMED N.V. |
| CIK | 1874252 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | P7 |
| Phone | 49 6131 5542860 |